Search results
New Ozempic Pill? Roche Shakes Up the Weight Loss Drug Market With Results
First for Women· 4 days agoThe competition is fierce, as you may have already seen with popular brands like Ozempic. And now,...
As Roche blocks Zydus’ Pertuzumab launch, experts see murky corporate rivalry - ET HealthWorld |...
The Economic Times· 4 days agoMumbai: Sigrima, Zydus Lifesciences’ biosimilar challenge to Roche’s breast cancer blockbuster brand...
Obesity pill from Roche shows promising weight loss in small study
BioPharma Dive· 5 days agoDive Brief: A closely watched obesity pill being developed by Roche helped people in a small Phase 1...
Roche reports long-term data from diabetic macular oedema treatment trial
Clinical Trials Arena· 4 days agoRoche has announced four-year results from the RHONE-X extension study, which evaluated the...
Roche’s foray into continuous glucose monitors dependent on AI efficacy: GlobalData
Financial Express· 6 days agoGlobalData, a data and analytics company, on Tuesday said that Roche’s artificial intelligence...
Roche reports positive early results in obesity drug trial - ET HealthWorld | Pharma
The Economic Times· 5 days agoLondon: Roche said on Wednesday its CT-996, a new drug being developed to treat obesity and type 2...
Roche reports positive data from Phase I obesity treatment trial
Clinical Trials Arena· 5 days agoRoche has reported positive topline data from the ongoing multi-part Phase I clinical trial of...
Roche’s AI based glucose monitoring system obtains CE marking - ET HealthWorld
The Economic Times· 6 days agoNew Delhi: Bio-technology developer Roche’s artificial intelligence (AI)-enabled continuous glucose...
Cheyenne Roche: The end and the beginning
Creston News Advertiser, Iowa· 2 days agoJul. 19—Monday as the Panthers fell in postseason baseball to Harlan, a year of athletics came to a close. I first started covering Southwest Iowa sports in the fall of 2022 when I followed ...
Caribou lays off staff; Roche walks away from Relay
BioPharma Dive· 5 days agoTogether, the moves will extend the company’s cash runway and focus resources on its CAR-T therapies, data for one of which it presented last month. —...